Back to top
more

Illumina (ILMN)

(Delayed Data from NSDQ)

$161.93 USD

161.93
3,100,660

+2.84 (1.79%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $161.85 -0.08 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (149 out of 247)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Perrigo (PRGO) Misses on Earnings in Q1, Reiterates View

by Zacks Equity Research

Perrigo (PRGO) misses earnings estimates but exceeds revenue expectations in Q1. The company reiterates its revenue and adjusted earnings outlook for 2018.

    Zacks Equity Research

    5 Top Stocks Showing Promise of an Earnings Beat

    by Zacks Equity Research

    Bet on five stocks that are likely to outdo earnings estimates.

      Zacks Equity Research

      Agios (AGIO) Q1 Loss Wider than Expected, Revenues Miss

      by Zacks Equity Research

      Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.

        Zacks Equity Research

        Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

        by Zacks Equity Research

        Zacks.com highlights: Illumina, Alarm.com Holdings, Copart and Vanda Pharmaceuticals

          Tirthankar Chakraborty headshot

          4 Top Efficient Stocks to Buy for Stellar Returns

          by Tirthankar Chakraborty

          A company with a favorable efficiency level is expected to provide stellar returns as it is believed to be positively correlated with its price performance.

            Zacks Equity Research

            Illumina (ILMN) Beats on Q1 Earnings, Lifts '18 Guidance

            by Zacks Equity Research

            Illumina's (ILMN) collaboration with Bristol-Myers Squibb and Loxo Oncology are likely to yield results in the near term.

              Zacks Equity Research

              Bristol-Myers Reports Positive Data in NSCLC Trial on Opdivo

              by Zacks Equity Research

              Bristol-Myers Squibb Company (BMY) announced positive results from the phase III trial, CheckMate -078 trial on immuno-oncology drug Opdivo among a predominantly Chinese population.

                Zacks Equity Research

                Can Solid Overall Growth Drive Illumina's (ILMN) Q1 Earnings?

                by Zacks Equity Research

                Illumina (ILMN) expected to gain from strong revenues at Product as well as Service and other segments in Q1.

                  Zacks Equity Research

                  Illumina Banks on Product Launches & Strategic Partnerships

                  by Zacks Equity Research

                  Illumina (ILMN) successfully broadens base by enriching its portfolio of sequencing products and building strategic partnerships with therapeutic and diagnostic service providers.

                    Zacks Equity Research

                    Illumina Banks on Strategic Partnerships, Competition Rife

                    by Zacks Equity Research

                    Illumina's (ILMN) recently-signed partnership to distribute Thermo Fisher's Ion AmpliSeq technology is encouraging.